On-X Heart Valve PROACT Trial Report
On-X Heart Valve PROACT Trial Preliminary Report Provides Evidence toward Maintaining Patients with Less Warfarin Preliminary Results of FDA-Approved PROACT Trial show the On-X® Valve continues to demonstrate tolerance of low INR seen in worldwide studies AUSTIN, TX — April 06, 2011 — On-X® Life Technologies, Inc. announced today that preliminary results from a Food…
Read MoreOn-X Heart Valve Shows Safety with Reduced Blood Thinners
On-X Heart Valve Shows Safety with Reduced Blood Thinners Early Data Reported From Large FDA IDE Clinical Trial is Encouraging New Orleans, LA — April 5, 2011 – Patients with a mechanical heart valve need lifelong treatment with blood-thinning drugs like warfarin − anticoagulants that prevent blood from clotting on the man-made material but also…
Read MoreClinical Update Thirty-Six: Anticoagulant Drugs
The Ignored Benefits of Anticoagulant Drugs In an aging population, anticoagulant drugs provide benefits that are often ignored in favor of repeated valve operations. Benefits of Warfarin Current heart valve selection criteria is heavily weighted toward tissue valve implants even when an increasing number of randomized or matched clinical studies show the risks of…
Read MoreClinical Update Thirty-Five: Lowered Anticoagulation
Lowered Anticoagulation Trial Preliminary Results The On-X® Prosthetic Heart Valve continues to demonstrate tolerance of low INR that has been seen in worldwide studies. A unique study of On-X heart valves The Prospective Randomized On-X Valve Anticoagulation Trial (PROACT) was initiated in 2006 and is currently ongoing in 36 centers throughout the United States…
Read MoreClinical Update Thirty-Four: On-X Heart Valve Outperform
On-X Heart Valves outperform tissue valves in a matched study On-X® Prosthetic Heart Valve patients in a prospective study matched to patients implanted with tissue valves showed a definite advantage in mortality.1 The On-X® Prosthetic Heart Valve provides lower mortality Study results reported at the recent Society of Thoracic Surgeons (STS) meeting in San…
Read MoreOn-X LTI to Host Satellite Symposium
On-X LTI to Host Satellite Symposium at Society of Thoracic Surgeons (STS) Meeting New Considerations for Prosthetic Valve Choice” challenges current prosthetic heart valve trends AUSTIN, TX — January 25, 2011 — On-X® Life Technologies, Inc. (On-X LTI) announced today that it will host a Satellite Symposium during the Society of Thoracic Surgeons meeting in…
Read MoreOn-X LTI Receives FDA Approval for AAP
On-X LTI Receives FDA Approval for Aortic Valve with Vascutek Graft Innovative On-X aortic valve is now available with market-leading pre-attached Gelweave Valsalva™ Vascular Prosthesis AUSTIN, TX — January 21, 2011 — On-X® Life Technologies, Inc. (On-X LTI) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market…
Read MoreOn-X Heart Valve Superior Performance
Large Canadian Heart Valve Study Provides Evidence of On-X® Heart Valve Superior Performance AUSTIN, TX — December 13, 2010 — On-X® Life Technologies, Inc. (On-X LTI), today announced the publication of results of a large, prospective multi-center Canadian trial with the On-X Prosthetic Heart Valve in the November issue of The Journal of Thoracic and…
Read MoreClinical Update Thirty-Three: On-X Pure Carbon Valve
Does the On-X Pure Carbon Valve behave like a mechanical or tissue valve? Results of an intermediate term study of 737 Canadian patients show decreased risk with the On-X® Prosthetic Heart Valve.1 A study published in the November 2010 issue of The Journal of Thoracic and Cardiovascular Surgery found approximately 30% improvement in aortic…
Read MoreClinical Update Thirty-Two: Mechanical Over Tissue
The advantage of mechanical over tissue prostheses in mitral patients A comprehensive study of mitral valve repair vs. mitral valve replacement reveals that the least acceptable outcomes occur in tissue valve mitral replacement patients. Clinicians at Duke University in North Carolina published a study that shows an expected advantage in survival for patients with…
Read More